SCHEMBL3401148

SCHEMBL3401148

Cc1c(NC(=O)Nc2ccc3nc(N[C@@H]4CCc5ccccc54)ccc3c2)ccnc1Br

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 5/20 0.37
HTR2B P41595 5/20 0.37
HPGDS O60760 1/20 0.37
CDK1 P06493 1/20 0.37
BRS3 P32247 1/20 0.37
MEN1 O00255 3/20 0.36
MAPT P10636 3/20 0.36
KMT2A Q03164 3/20 0.36
NPC1 O15118 2/20 0.36
MAPK1 P28482 2/20 0.36
POLB P06746 1/20 0.36
NPY1R P25929 1/20 0.35
PFKFB3 Q16875 1/20 0.35
NTRK1 P04629 2/20 0.35
ALDH1A1 P00352 2/20 0.35
IMPDH2 P12268 1/20 0.35
HCRTR1 O43613 1/20 0.35
HCRTR2 O43614 1/20 0.35
TP53 P04637 1/20 0.35
CYP1A2 P05177 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3403165 0.83 KMT2A (0.48) HPGDSMEN1MAPTKMT2ANPC1
SCHEMBL3402764 0.83 NPC1 (0.38) HPGDSCDK1MEN1MAPTKMT2A
SCHEMBL3398588 0.83 SMARCA2 (0.46) HPGDSMEN1MAPTKMT2ANPC1
SCHEMBL3405693 0.83 NPC1 (0.45) HPGDSMEN1MAPTKMT2ANPC1
SCHEMBL3411790 0.82 NPC1 (0.42) HPGDSBRS3MEN1MAPTKMT2A
SCHEMBL3400249 0.82 NPSR1 (0.50) MEN1MAPTKMT2ANPC1POLB
SCHEMBL3411464 0.81 HPGDS (0.41) HPGDSMEN1MAPTKMT2ANPC1
SCHEMBL3404267 0.81 KMT2A (0.52) HPGDSMEN1MAPTKMT2ANPC1
SCHEMBL3398554 0.81 NPC1 (0.52) HPGDSMEN1MAPTKMT2ANPC1
SCHEMBL4109902 0.80 MAPT (0.44) HTR2CHTR2BHPGDSMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188284-B2 2-aminoquinolines HOFFMAN-LA ROCHE INC. (US) 2012-05-29 US claimed
US-20090227583-A1 2-AMINOQUINOLINES F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2009-09-10 US claimed
US-8188284-B2 2-aminoquinolines HOFFMAN-LA ROCHE INC. (US) 2012-05-29 US disclosed
EP-2252372-A1 2-AMINOQUINOLINES F. Hoffmann-La Roche AG (CH) 2010-11-24 EP disclosed
WO-2009109502-A1 2-AMINOQUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2009-09-11 WO disclosed
US-20090227583-A1 2-AMINOQUINOLINES F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2009-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227583-A1 2-AMINOQUINOLINES HTR5A, HTR2C, HTR2B HTR2C 2/4885HTR2B 3/4885HPGDS 2010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.